(firstQuint)A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD.

 This is a randomized, six-way crossover study to determine the efficacy and dose-response profile of SUN101.

 The study population will consist of subjects 40 to 65 years-old (inclusive), with a diagnosis of moderate to severe COPD.

 Aclidinium bromide 400 mcg bid will be given as an active comparator.

 The study will be double-blind for SUN-101 and placebo and will be open-label for aclidinium.

.

 A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD@highlight

Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD.

 Aclidinium bromide 400 mcg 2x a day will be given as an active comparator.

